Title : An evaluation of olaparib for the treatment of pancreatic cancer.

Pub. Date : 2021 Mar

PMID : 33094666






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 EXPERT OPINION: Olaparib was compared to placebo in a randomized double blind trial in cases with advanced pancreatic cancer and germline BRCA1/2 mutations, with a clinical response or stable disease after at least 16 weeks of platinum based chemotherapy. olaparib BRCA1 DNA repair associated Homo sapiens